Bendamustine: all 237 studies that test it
Page 3 of 3. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.
- Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT01078142Phase 1/2
- Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple MyelomaCompletedNCT01045681Phase 2
- Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple MyelomaCompletedNCT01042704Phase 1
- Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With BendamustineCompletedNCT01022021Early Phase 1
- Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT01015248Phase 2
- Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT01002703Phase 1/2
- Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaCompletedNCT00992134Phase 2
- Bendamustine Plus Rituximab Versus CHOP Plus RituximabCompletedNCT00991211Phase 3
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaCompletedNCT00987493Phase 1/2
- Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.CompletedNCT00963534Phase 1/2
- Bendamustine in Patients With Refractory or Relapsed T-cell LymphomaCompletedNCT00959686Phase 2
- Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00951457Phase 1/2
- Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00947388Phase 1
- S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00939328Phase 2
- Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
- Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid TumorsTerminatedNCT00879073Phase 1
- Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWithdrawnNCT00872976Phase 1
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00868413Phase 1
- Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)CompletedNCT00864942Phase 1
- Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory MalignancyCompletedNCT00863850Phase 1
- Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid TumorsCompletedNCT00837928Phase 1
- Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00831597Phase 2
- A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's LymphomaCompletedNCT00825149Phase 1
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00769522Phase 3
- Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00758693Phase 2
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaCompletedNCT00740415Phase 2
- A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast CancerCompletedNCT00661739Phase 1
- Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00612183Phase 2
- A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00389051Phase 1
- Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00274989Phase 2
- Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00274963Phase 2
- Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)CompletedNCT00204620Phase 2
- Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)Status unknownNCT00168922Phase 2
- Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to RituximabCompletedNCT00139841Phase 3
- SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2
- Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's LymphomaCompletedNCT00069758Phase 2